Drugs / Ex vivo immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00399971 | Nov 2002 → Jun 2009 | aplastic anemia | Shenzhen Zhongxing Yangfan Biotech Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex vivo immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00399971 ↗ |
| Modality | Cell therapy | “Allogeneic and autologous ex vivo activated immune cells” NCT00399971 ↗ |
| Route | Intravenous | “are given intravenously” NCT00399971 ↗ |